secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-06-08T12:31:21+00:00
Accession:  0001104659-26-071195
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools to merge with Treeline Biosciences in all-stock deal; LAB stockholders to own ~16%
--------------------------------------------------------------------------------

- All-stock merger; Treeline valued at $2.5B, Standard BioTools at ~$460M; combined co. to be named Treeline Biosciences Holdings.
- Former LAB stockholders to hold ~16% of combined co., Treeline stockholders ~84%; closing expected H2 2026.
- Legacy mass cytometry/microfluidics business to be sold or wound down; CVRs issued to LAB stockholders for proceeds.
- Treeline CEO Josh Bilenker to lead combined co.; board to have 12 members, 10 from Treeline, 2 from LAB.
- Voting agreements covering ~39% of LAB shares; termination fee of $16.1M payable by LAB in certain circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926071195/0001104659-26-071195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926071195/tm2617100d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-071195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer